Perfil
Timothy Siegert is the founder of Allyx Therapeutics, Inc. He holds the title of Chief Operating Officer at the company.
Cargos activos de Timothy Siegert
| Empresas | Cargo | Inicio |
|---|---|---|
Allyx Therapeutics, Inc.
 Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | Fundador | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Allyx Therapeutics, Inc.
Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | Commercial Services |
- Bolsa de valores
- Insiders
- Timothy Siegert
